Home > Healthcare > Medical Devices > Therapeutic Devices > structural heart devices market
Get a free sample of Structural Heart Devices Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Structural Heart Devices Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The structural heart devices industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products with improved efficiency and cost-effectiveness is among a key market strategy for structural heart devices manufacturers. Some of the leading industry players including Abbott Laboratories, Boston Scientific Corporation, Inc., Medtronic plc, Lepu Medical Technology (Beijing) Co., Ltd., and Edwards Lifesciences Corporation., Ltd, among others have a substantial presence in the market.
Some of the eminent market participants operating in the structural heart devices industry include:
Structural heart devices industry size was USD 11.3 billion in 2023 and is expected to register 8.8% CAGR from 2024-2032 owing to the growing burden of cardiovascular diseases, favorable reimbursement scenarios and the rising preference for minimally invasive procedures worldwide.
AtriCure, Inc., Biomerics, LLC, Boston Scientific Corporation, Braile Biomedica, Cryolife Inc., Edwards Lifesciences Corporation, JenaValve Technology, Inc., Lepu Medical Technology (Beijing) Co., Ltd., and LivaNova PLC are some of the major structural heart devices companies worldwide.
North America structural heart devices industry reached USD 3.8 billion in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the presence of a sophisticated healthcare infrastructure, coupled with high healthcare expenditure in the region.
The heart valve devices segment recorded over USD 4.7 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to the high incidence of heart diseases necessitating widespread adoption of devices.